Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene therapy targeting the blood–brain barrier improves neurological symptoms in a model of genetic MCT8 deficiency

5 Aug 2022

Abstract excerpt

A genetic deficiency of the solute carrier monocarboxylate transporter 8 (MCT8), termed Allan-Herndon-Dudley syndrome, is an important cause of X-linked intellectual and motor disability. MCT8 transports thyroid hormones across cell membranes. While thyroid hormone analogues improve peripheral changes of MCT8 deficiency, no treatment of the neurological symptoms is available so far. Therefore, we tested a gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetics and Neurodevelopmental Disorders
Share to Mitochondrial Function and Pathology
Share to Thyroid Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35929549
DOI: 10.1093/brain/awac243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene therapy targeting the blood–brain barrier improves neurological symptoms in a model of genetic MCT8 deficiencyPMID 35929549Read ↗

Gene therapy targeting the blood-brain barrier improves neurological symptoms in a model of genetic MCT8 deficiencySemantic proximity Read ↗

AAV9-MCT8 delivery at juvenile stage ameliorates neurological and behavioral deficits in an Allan-Herndon-Dudley Syndrome mouse modelSemantic proximity Read ↗

AAV9-MCT8 Delivery at Juvenile Stage Ameliorates Neurological and Behavioral Deficits in a Mouse Model of MCT8-Deficiency.Semantic proximity Read ↗

Monocarboxylate Transporter 8 Deficiency: From Pathophysiological Understanding to Therapy Development.Semantic proximity Read ↗

Zebrafish as a model for monocarboxyl transporter 8-deficiency.Semantic proximity Read ↗

Decreased cellular uptake and metabolism in Allan-Herndon-Dudley syndrome (AHDS) due to a novel mutation in the MCT8 thyroid hormone transporterSemantic proximity Read ↗

Neural Alterations and Hyperactivity of the Hypothalamic-Pituitary-Thyroid Axis in Oatp1c1 Deficiency.Semantic proximity Read ↗

Thyroid hormone transporters.Semantic proximity Read ↗

Disorder of thyroid hormone transport into the tissues.Semantic proximity Read ↗

Mechanisms of disease: psychomotor retardation and high T3 levels caused by mutations in monocarboxylate transporter 8.Semantic proximity Read ↗

Thyroid hormone transporters in health and disease.Semantic proximity Read ↗

Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.